Tom 5, Nr 2 (2020)
Artykuły przeglądowe / Review articles
Opublikowany online: 2020-04-10
Pobierz cytowanie

Oncogeriatrics (part 5.). The role of comorbidities in older patients with cancer

Urszula Skorus, Jakub Kenig
Biuletyn Polskiego Towarzystwa Onkologicznego Nowotwory 2020;5(2):71-76.

dostęp płatny

Tom 5, Nr 2 (2020)
Artykuły przeglądowe / Review articles
Opublikowany online: 2020-04-10

Streszczenie

Comorbidity is defined as the presence of one or more additional conditions co-occurring with primary indices. Comorbidity is common in older cancer patients. Its prevalence, however, is difficult to determine and varies by cancer site. There is no single reason for which comorbidity and cancer coexist, but chronic diseases and cancer are both common in older age and share many risk factors. 

There is no consensus on how should comorbidity be measured. Even though many comorbidity indices have been developed so far, no unified, widely used instrument exists. 

Patients with comorbidities have worse outcomes compared to those with no such conditions. They may experience diagnostic and therapeutic delay and be disqualified from radical treatment more often. Moreover, they are more likely to suffer from treatment-related complications and have worse overall survival. 

It seems important to assess the comorbidity status as a part of individualised oncologic treatment planning. However, as data regarding its significance are insufficient and in many cases conflicting, patients with comorbidity should not be routinely considered as not fit enough for a radical treatment. Therefore, to adequately address all of the concerns that have been raised, a broader participation of older, comorbid patients in clinical trials is needed. 

Streszczenie

Comorbidity is defined as the presence of one or more additional conditions co-occurring with primary indices. Comorbidity is common in older cancer patients. Its prevalence, however, is difficult to determine and varies by cancer site. There is no single reason for which comorbidity and cancer coexist, but chronic diseases and cancer are both common in older age and share many risk factors. 

There is no consensus on how should comorbidity be measured. Even though many comorbidity indices have been developed so far, no unified, widely used instrument exists. 

Patients with comorbidities have worse outcomes compared to those with no such conditions. They may experience diagnostic and therapeutic delay and be disqualified from radical treatment more often. Moreover, they are more likely to suffer from treatment-related complications and have worse overall survival. 

It seems important to assess the comorbidity status as a part of individualised oncologic treatment planning. However, as data regarding its significance are insufficient and in many cases conflicting, patients with comorbidity should not be routinely considered as not fit enough for a radical treatment. Therefore, to adequately address all of the concerns that have been raised, a broader participation of older, comorbid patients in clinical trials is needed. 

Pobierz cytowanie

Słowa kluczowe

older patient; comorbidity; multimorbidity; frailty

Informacje o artykule
Tytuł

Oncogeriatrics (part 5.). The role of comorbidities in older patients with cancer

Czasopismo

Biuletyn Polskiego Towarzystwa Onkologicznego Nowotwory

Numer

Tom 5, Nr 2 (2020)

Strony

71-76

Data publikacji on-line

2020-04-10

Rekord bibliograficzny

Biuletyn Polskiego Towarzystwa Onkologicznego Nowotwory 2020;5(2):71-76.

Słowa kluczowe

older patient
comorbidity
multimorbidity
frailty

Autorzy

Urszula Skorus
Jakub Kenig

Referencje (61)
  1. Koczwara B. ed. Cancer and Chronic Conditions. Springer, Singapore 2016.
  2. Fortin M, Dionne J, Pinho G, et al. Randomized controlled trials: do they have external validity for patients with multiple comorbidities? Ann Fam Med. 2006; 4(2): 104–108.
  3. Satariano WA, Silliman RA. Comorbidity: implications for research and practice in geriatric oncology. Crit Rev Oncol Hematol. 2003; 48(2): 239–248.
  4. Feinstein AR. THE PRE-THERAPEUTIC CLASSIFICATION OF CO-MORBIDITY IN CHRONIC DISEASE. J Chronic Dis. 1970; 23(7): 455–468.
  5. Valderas JM, Starfield B, Sibbald B, et al. Defining comorbidity: implications for understanding health and health services. Ann Fam Med. 2009; 7(4): 357–363.
  6. R R. Santriono Refki, “سلطنة عمانペインクリニック学会治療指針2,” ペインクリニック学会治療指針. 2019; 4(1): 75–84.
  7. Linn BS, Linn MW, Gurel L. Cumulative illness rating scale. J Am Geriatr Soc. 1968; 16(5): 622–626.
  8. Kaplan M, Feinstein A. The importance of classifying initial co-morbidity in evaluating the outcome of diabetes mellitus. Journal of Chronic Diseases. 1974; 27(7-8): 387–404.
  9. Charlson M, Pompei P, Ales K, et al. A new method of classifying prognostic comorbidity in longitudinal studies: Development and validation. Journal of Chronic Diseases. 1987; 40(5): 373–383.
  10. Stier D, Greenfield S, Lubeck D, et al. Quantifying comorbidity in a disease-specific cohort: adaptation of the total illness burden index to prostate cancer. Urology. 1999; 54(3): 424–429.
  11. Satariano WA, Ragland DR. The Effect of Comorbidity on 3-Year Survival of Women with Primary Breast Cancer. Ann Intern Med. 1994; 120: 104–110.
  12. Elixhauser A, Steiner C, Harris DR, et al. Comorbidity measures for use with administrative data. Med Care. 1998; 36(1): 8–27.
  13. van Walraven C, Austin PC, Jennings A, et al. A modification of the Elixhauser comorbidity measures into a point system for hospital death using administrative data. Med Care. 2009; 47(6): 626–633.
  14. Piccirillo J, Feinstein A. Clinical symptoms and comorbidity: significance for the prognostic classification of cancer. Cancer. 1996; 77(5): 834–842, doi: 10.1002/(sici)1097-0142(19960301)77:5<834::aid-cncr5>3.0.co;2-e.
  15. Evans DC, Cook CH, Christy JM, et al. Comorbidity-polypharmacy scoring facilitates outcome prediction in older trauma patients. J Am Geriatr Soc. 2012; 60(8): 1465–1470.
  16. Sarftati D. In: Cancer and Chronic Conditions. Springer, Singapore 2016.
  17. Maestu I, Muñoz J, Gómez-Aldaraví L, et al. Assessment of functional status, symptoms and comorbidity in elderly patients with advanced non-small-cell lung cancer (NSCLC) treated with gemcitabine and vinorelbine. Clin Transl Oncol. 2007; 9(2): 99–105.
  18. Maione P, Perrone F, Gallo C, et al. Pretreatment quality of life and functional status assessment significantly predict survival of elderly patients with advanced non-small-cell lung cancer receiving chemotherapy: a prognostic analysis of the multicenter Italian lung cancer in the elderly study. J Clin Oncol. 2005; 23(28): 6865–6872.
  19. Moscetti L, Nelli F, Padalino D, et al. Gemcitabine and cisplatin in the treatment of elderly patients with advanced non-small cell lung cancer: impact of comorbidities on safety and efficacy outcome. J Chemother. 2005; 17(6): 685–692.
  20. Cummings LC, Kou TD, Schluchter MD, et al. Outcomes after endoscopic versus surgical therapy for early esophageal cancers in an older population. Gastrointest Endosc. 2016; 84(2): 232–240.e1.
  21. Tougeron D, et al. Esophageal cancer in the elderly: An analysis of the factors associated with treatment decisions and outcomes. BMC Cancer. 2010; 10.
  22. Anderson SE, Minsky BD, Bains M, et al. Combined modality chemoradiation in elderly oesophageal cancer patients. Br J Cancer. 2007; 96(12): 1823–1827.
  23. Dziemiańczyk-Pakieła D, et al. How comorbidities affect the surgical treatment planning in elderly patients with head and neck cancer? J Educ Heal Sport VO - 8. 2018; 8(5): 22.
  24. Luo R, Giordano SH, Freeman JL, et al. Referral to medical oncology: a crucial step in the treatment of older patients with stage III colon cancer. Oncologist. 2006; 11(9): 1025–1033.
  25. Hu CY, Delclos GL, Chan W, et al. Assessing the initiation and completion of adjuvant chemotherapy in a large nationwide and population-based cohort of elderly patients with stage-III colon cancer. Med Oncol. 2011; 28(4): 1062–1074.
  26. Neugut AI, Matasar M, Wang X, et al. Duration of adjuvant chemotherapy for colon cancer and survival among the elderly. J Clin Oncol. 2006; 24(15): 2368–2375.
  27. Schonberg MA, Marcantonio ER, Li D, et al. Breast cancer among the oldest old: tumor characteristics, treatment choices, and survival. J Clin Oncol. 2010; 28(12): 2038–2045.
  28. Coebergh JW, Janssen-Heijnen ML, Razenberg PP. Prevalence of co-morbidity in newly diagnosed patients with cancer: a population-based study. Crit Rev Oncol Hematol. 1998; 27(2): 97–100.
  29. Kieszak SM, Flanders WD, Kosinski AS, et al. A comparison of the Charlson comorbidity index derived from medical record data and administrative billing data. J Clin Epidemiol. 1999; 52(2): 137–142.
  30. Sarfati D, Hill S, Purdie G, et al. How well does routine hospitalisation data capture information on comorbidity in New Zealand? N Z Med J. 2010; 123(1310): 50–61.
  31. Doorn Cv, Bogardus S, Williams C, et al. Risk adjustment for older hospitalized persons. Journal of Clinical Epidemiology. 2001; 54(7): 694–701.
  32. Jørgensen TL, Hallas J, Friis S, et al. Comorbidity in elderly cancer patients in relation to overall and cancer-specific mortality. Br J Cancer. 2012; 106(7): 1353–1360.
  33. Gupta SK, Lamont EB. Patterns of presentation, diagnosis, and treatment in older patients with colon cancer and comorbid dementia. J Am Geriatr Soc. 2004; 52(10): 1681–1687.
  34. Clerencia-Sierra M, Calderón-Larrañaga A, Martínez-Velilla N, et al. Multimorbidity Patterns in Hospitalized Older Patients: Associations among Chronic Diseases and Geriatric Syndromes. PLoS One. 2015; 10(7): e0132909.
  35. Mounce LTA, Price S, Valderas JM, et al. Comorbid conditions delay diagnosis of colorectal cancer: a cohort study using electronic primary care records. Br J Cancer. 2017; 116(12): 1536–1543.
  36. Sewitch MJ, Fournier C, Dawes M, et al. Do physician recommendations for colorectal cancer screening differ by patient age? Can J Gastroenterol. 2007; 21(7): 435–438.
  37. Blustein J, Weiss LJ. Factors Related to Health , Functioning , and Age. 1998.
  38. Fleming ST, Pursley HG, Newman B, et al. Comorbidity as a predictor of stage of illness for patients with breast cancer. Med Care. 2005; 43(2): 132–140.
  39. Terret C, Castel-Kremer E, Albrand G, et al. Effects of comorbidity on screening and early diagnosis of cancer in elderly people. Lancet Oncol. 2009; 10(1): 80–87.
  40. Søgaard M, Thomsen RW, Bossen KS, et al. The impact of comorbidity on cancer survival: a review. Clin Epidemiol. 2013; 5(Suppl 1): 3–29.
  41. Roxburgh C, McDonald A, Salmond J, et al. Adjuvant chemotherapy for resected colon cancer: comparison of the prognostic value of tumour and patient related factors. Int J Colorectal Dis. 2011; 26(4): 483–492.
  42. Sarfati D, Hill S, Blakely T, et al. The effect of comorbidity on the use of adjuvant chemotherapy and survival from colon cancer: a retrospective cohort study. BMC Cancer. 2009; 9: 116.
  43. Riihimäki M, Thomsen H, Brandt A, et al. Death causes in breast cancer patients. Ann Oncol. 2012; 23(3): 604–610.
  44. Forte V, et al. Obesity, Diabetes, the Cardiorenal Syndrome, and Risk for Cancer. Cardiorenal Med. 2012; 2(2): 143–162.
  45. Sainz J, Rudolph A, Hoffmeister M, et al. Effect of type 2 diabetes predisposing genetic variants on colorectal cancer risk. J Clin Endocrinol Metab. 2012; 97(5): E845–E851.
  46. Sassano A, Platanias LC. Statins in tumor suppression. Cancer Lett. 2008; 260(1-2): 11–19.
  47. Khuder SA, Herial NA, Mutgi AB, et al. Nonsteroidal antiinflammatory drug use and lung cancer: a metaanalysis. Chest. 2005; 127(3): 748–754.
  48. Takkouche B, Regueira-Méndez C, Etminan M. Breast cancer and use of nonsteroidal anti-inflammatory drugs: a meta-analysis. J Natl Cancer Inst. 2008; 100(20): 1439–1447.
  49. Puts MTE, Tapscott B, Fitch M, et al. A systematic review of factors influencing older adults' decision to accept or decline cancer treatment. Cancer Treat Rev. 2015; 41(2): 197–215.
  50. Berglund A, Wigertz A, Adolfsson J, et al. Impact of comorbidity on management and mortality in women diagnosed with breast cancer. Breast Cancer Res Treat. 2012; 135(1): 281–289.
  51. Cykert S, Dilworth-Anderson P, Monroe MH, et al. Factors associated with decisions to undergo surgery among patients with newly diagnosed early-stage lung cancer. JAMA. 2010; 303(23): 2368–2376.
  52. van Gestel YR, Lemmens VE, de Hingh IH, et al. Influence of comorbidity and age on 1-, 2-, and 3-month postoperative mortality rates in gastrointestinal cancer patients. Ann Surg Oncol. 2013; 20(2): 371–380.
  53. Janssen-Heijnen MLG, Maas HA, Houterman S, et al. Comorbidity in older surgical cancer patients: influence on patient care and outcome. Eur J Cancer. 2007; 43(15): 2179–2193.
  54. Hamakawa T, Kurokawa Y, Mikami J, et al. Risk factors for postoperative complications after gastrectomy in gastric cancer patients with comorbidities. Surg Today. 2016; 46(2): 224–228.
  55. Kim W, Song KY, Lee HJ, et al. The impact of comorbidity on surgical outcomes in laparoscopy-assisted distal gastrectomy: a retrospective analysis of multicenter results. Ann Surg. 2008; 248(5): 793–799.
  56. Schneider EB, Hyder O, Brooke BS, et al. Patient readmission and mortality after colorectal surgery for colon cancer: impact of length of stay relative to other clinical factors. J Am Coll Surg. 2012; 214(4): 390–398; discussion 398.
  57. Lee L, Cheung WY, Atkinson E, et al. Impact of comorbidity on chemotherapy use and outcomes in solid tumors: a systematic review. J Clin Oncol. 2011; 29(1): 106–117.
  58. Hu CY, Delclos GL, Chan W, et al. Assessing the initiation and completion of adjuvant chemotherapy in a large nationwide and population-based cohort of elderly patients with stage-III colon cancer. Med Oncol. 2011; 28(4): 1062–1074.
  59. Hershman DL, Wang X, McBride R, et al. Delay in initiating adjuvant radiotherapy following breast conservation surgery and its impact on survival. Int J Radiat Oncol Biol Phys. 2006; 65(5): 1353–1360.
  60. Ely MR, Romero SA, Sieck DC, et al. A single dose of histamine-receptor antagonists before downhill running alters markers of muscle damage and delayed-onset muscle soreness. J Appl Physiol (1985). 2017; 122(3): 631–641.
  61. Unger JM, Hershman DL, Fleury ME, et al. Association of Patient Comorbid Conditions with Cancer Clinical Trial Participation. JAMA. 2019; 5(3): 326–333.

Ważne: serwis https://journals.viamedica.pl/ wykorzystuje pliki cookies. Więcej >>

Używamy informacji zapisanych za pomocą plików cookies m.in. w celach statystycznych, dostosowania serwisu do potrzeb użytkownika (np. język interfejsu) i do obsługi logowania użytkowników. W ustawieniach przeglądarki internetowej można zmienić opcje dotyczące cookies. Korzystanie z serwisu bez zmiany ustawień dotyczących cookies oznacza, że będą one zapisane w pamięci komputera. Więcej informacji można znaleźć w naszej Polityce prywatności.

Czym są i do czego służą pliki cookie możesz dowiedzieć się na stronie wszystkoociasteczkach.pl.

Wydawcą serwisu jest VM Media sp. z o.o. VM Group sp.k., ul. Świętokrzyska 73, 80–180 Gdańsk
tel.:+48 58 320 94 94, e-mail: viamedica@viamedica.pl